IL17A and psoriasis: IL-17 as a novel pharmacological target has expanded the scope of drug development for various autoimmune diseases10, of which, secukinumab has proven efficacy in psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondylarthritis, and enthesis-related arthritis.